These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 3816020)

  • 1. Evidence for altered catalytic properties of the cytochrome P-450 involved in sparteine oxidation in poor metabolizers.
    Osikowska-Evers B; Dayer P; Meyer UA; Robertz GM; Eichelbaum M
    Clin Pharmacol Ther; 1987 Mar; 41(3):320-5. PubMed ID: 3816020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A sensitive capillary GC assay for the determination of sparteine oxidation products in microsomal fractions of human liver.
    Osikowska-Evers BA; Eichelbaum M
    Life Sci; 1986 May; 38(19):1775-82. PubMed ID: 3702606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The genetic polymorphism of sparteine metabolism.
    Eichelbaum M; Reetz KP; Schmidt EK; Zekorn C
    Xenobiotica; 1986 May; 16(5):465-81. PubMed ID: 3739368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sparteine oxidation polymorphism in Greenlanders living in Denmark.
    Brøsen K
    Br J Clin Pharmacol; 1986 Oct; 22(4):415-9. PubMed ID: 3768256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Sparteine oxidation by hepatic cytochrome P-450 in patients with Parkinson's disease].
    Yoshino H; Hattori Y; Imai H; Narabayashi H; Chiba K
    Rinsho Shinkeigaku; 1993 Mar; 33(3):261-5. PubMed ID: 8334787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sparteine oxidation polymorphism in Denmark.
    Brøsen K; Otton SV; Gram LF
    Acta Pharmacol Toxicol (Copenh); 1985 Nov; 57(5):357-60. PubMed ID: 4090995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidation. Characterization of bufuralol 1'-hydroxylation in liver microsomes of in vivo phenotyped carriers of the genetic deficiency.
    Dayer P; Kronbach T; Eichelbaum M; Meyer UA
    Biochem Pharmacol; 1987 Dec; 36(23):4145-52. PubMed ID: 3689440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship between paroxetine and the sparteine oxidation polymorphism.
    Sindrup SH; Brøsen K; Gram LF; Hallas J; Skjelbo E; Allen A; Allen GD; Cooper SM; Mellows G; Tasker TC
    Clin Pharmacol Ther; 1992 Mar; 51(3):278-87. PubMed ID: 1531950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphic drug oxidation in humans.
    Eichelbaum M
    Fed Proc; 1984 May; 43(8):2298-302. PubMed ID: 6714436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan.
    Kévorkian JP; Michel C; Hofmann U; Jacqz-Aigrain E; Kroemer HK; Peraldi MN; Eichelbaum M; Jaillon P; Funck-Brentano C
    Clin Pharmacol Ther; 1996 May; 59(5):583-92. PubMed ID: 8646830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation.
    Meyer UA; Gut J; Kronbach T; Skoda C; Meier UT; Catin T; Dayer P
    Xenobiotica; 1986 May; 16(5):449-64. PubMed ID: 2874666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of cytochrome P450 2D6-catalyzed sparteine metabolism in humans.
    Ebner T; Meese CO; Eichelbaum M
    Mol Pharmacol; 1995 Dec; 48(6):1078-86. PubMed ID: 8848008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Genetic polymorphism in sparteine oxidation--occurrence in healthy volunteers in Slovakia].
    Holomán J; Glasa J; Veningerová M; Prachar V; Lukácsová M
    Bratisl Lek Listy; 1997 Feb; 98(2):86-90. PubMed ID: 9264814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine.
    Skjelbo E; Brøsen K; Hallas J; Gram LF
    Clin Pharmacol Ther; 1991 Jan; 49(1):18-23. PubMed ID: 1988236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sparteine oxidation polymorphism: a family study.
    Brøsen K; Otton SV; Gram LF
    Br J Clin Pharmacol; 1986 Jun; 21(6):661-7. PubMed ID: 3741716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a "cocktail" study design.
    Schellens JH; van der Wart JH; Brugman M; Breimer DD
    J Pharmacol Exp Ther; 1989 May; 249(2):638-45. PubMed ID: 2724144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Steady-state plasma levels of clomipramine and its metabolites: impact of the sparteine/debrisoquine oxidation polymorphism. Danish University Antidepressant Group.
    Nielsen KK; Brøsen K; Gram LF
    Eur J Clin Pharmacol; 1992; 43(4):405-11. PubMed ID: 1451721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of a common genetic defect of cytochrome P-450 function (debrisoquine-sparteine type polymorphism)--increased Michaelis is Constant (Km) and loss of stereoselectivity of bufuralol 1'-hydroxylation in poor metabolizers.
    Dayer P; Gasser R; Gut J; Kronbach T; Robertz GM; Eichelbaum M; Meyer UA
    Biochem Biophys Res Commun; 1984 Nov; 125(1):374-80. PubMed ID: 6508804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of relationship between quinidine pharmacokinetics and the sparteine oxidation polymorphism.
    Nielsen F; Rosholm JU; Brøsen K
    Eur J Clin Pharmacol; 1995; 48(6):501-4. PubMed ID: 8582470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of enzyme induction on polymorphic sparteine oxidation.
    Eichelbaum M; Mineshita S; Ohnhaus EE; Zekorn C
    Br J Clin Pharmacol; 1986 Jul; 22(1):49-53. PubMed ID: 3741726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.